AzTrials
AzTrials

LipodystrophyIL-7normNCT01784289

Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity

An observational study of Lipodystrophy and Obesity, run by University Hospital, Lille at 5 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

White adipose tissue-related diseases spread from excess (obesity) to lack (lipoatrophies) through aberrant distribution (lipodystrophies), these 3 different disorders being paradoxically able to induce a metabolic insulin resistance syndrome. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Lipodystrophy, Obesity, Type 2 Diabetes
How many people
126 participants
Where
5 sitesFrance
Study dates
Jun 2010to Jun 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients with lipodystrophy : Endocrinology Departments of Lille , Amiens, Caen, Rouen and Reims University hospitals. Obese (diabetics and non diabetics) and normal weight patients : Endocrinology - Metabolism, Endocrine Surgery and Nutrition Departments, Lille University Hospital

Who may be able to join

  • Male and Female
  • More than 18 years old
  • with lipodystrophic syndrome (familial, partial, genetically determined), diabetics or not, obese or not
  • Patients with lipodystrophy non related to a lamine A/C gene mutation, diabetics or not, obese or not
  • Obese without diabetes (BMI> 30)
  • Obese (BMI>30) and diabetes according to ADA criteria
  • Normal weight patients (18< BMI< 25)
  • Agreement for the establishment of a serum bank and a plasma bank

Who cannot join

  • Unable to receive enlightened information
  • Refusal to sign the consent
  • Corticosteroids (including inhaled), other immunosuppressing treatments (systemic disease for example) or immunomodulators (eg interferon);
  • Creatinin > 15 mg / L
  • Sepsis
  • Progressing cancers or autoimmune diseases;
Show all 17Show fewer
  • Treatment, disease or other condition that may affect the rate of IL-7 (as some contraceptives with estrogens)
  • Bleeding disorders (due to disease or treatment)
  • Active alcohol Intoxication
  • Psychiatric pathology (after psychiatric consultation)
  • Active infection including hepatitis C or HIV;
  • Age under 18 years
  • Participation in another study excluded the possibility of participating in another protocol
  • BMI > 60
  • Secondary diabetes
  • No social security
  • Pregnant or lactating women, patients under guardianship, persons deprived of liberty

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

France5 sites
  • Amiens University Hospital

    Amiens, 80054

  • Caen University Hospital

    Caen, 14032

  • Lille University Hospital

    Lille, 59037

  • Reims University Hospital

    Reims, 51092

  • Rouen University Hospital

    Rouen, 76031

Other trials in France

About this study

Official title: Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophies According to Fat Mass and Glucose Metabolism

White adipose tissue-related diseases spread from excess (obesity) to lack (lipoatrophies) through aberrant distribution (lipodystrophies), these 3 different disorders being paradoxically able to induce a metabolic insulin resistance syndrome. The respective part of quantitative and qualitative anomalies of adipose tissue, gluco- and lipo-toxicity, liver and muscle insulin resistance, low-grade fat inflammation and immune alterations are not perfectly understood in the metabolic syndrome yet. Therefore, the aim of this study is to assess different cytokines, especially interleukin 7, and metabolic parameters as well as fat mass distribution with DEXA and RMN, in different models of fat distribution, including normal-weight, obese and lipodystrophic patients. A plasma serum, gene and adipose tissue bank will be constituted at the same time to improve our knowledge in disorders linking fat mass, insulin resistance and immunity, especially in lipodystrophies, a rare monogenic model of insulin resistance.

Read the detailed description

Rational: In reason of its ability to store fatty acids and to secrete numerous pro-inflammatory cytokines, the adipocyte appears as a key cell in the regulation of energy metabolism and immune response. Moreover, it has been recently shown that adipocytes play a role in the recruitment of cells involved in innate and adaptive immunity in adipose tissue.

White adipose tissue-related diseases are numerous, spreading from excess (obesity) to a complete (lipoatrophies) or partial lack (lipodystrophies), these 3 different disorders being paradoxically able to induce a metabolic insulin resistance syndrome.

Among the involved cytokines, interleukin-7 (IL-7), mostly known for its immune functions, also participates to the quantitative and qualitative balance of fat mass. Thus, IL-7 over-expression in an animal model induces a lipodystrophic syndrome with insulin resistance whereas in humans, a preliminary study shows that LMNA-linked lipodystrophies are associated with an increase of blood IL-7 levels. IL-7 also participates to reactivation of autoimmunity in patients suffering from auto-immune type 1 after islet transplantation.

Therefore, the aim of this study is to assess different cytokines, especially interleukin 7, and metabolic parameters levels as well as fat mass distribution, in different models of fat distribution, including normal-weighed, obese and lipodystrophic patients. A plasma serum, gene and tissue bank will be constituted in order to improve our knowledge in disorders linking fat mass, insulin resistance and immunity, especially in lipodystrophies, a rare monogenic model of insulin resistance.

Patients: The included patients correspond to subjects of either normal body weight, or obese, or suffering from lipodystrophic syndrome, whatever their type 2 diabetes status.

Methods: Blood IL-7 levels, other immune and/or pro-inflammatory cytokines, lymphocytes immuno-phenotype as well as metabolic parameters will be characterized. Fat mass will be assessed with non-invasive methods (DEXA and RMN). A plasma, serum and gene bank will be constituted. As well as an adipose tissue bank in patients who will have a surgery (especially plastic surgery in lipodystrophic patients), in order to cryo-preserve it and to define the inflammatory status of this tissue thanks to histological and molecular analysis.

Main judgment criteria: The main judgment criteria will be IL-7 blood levels in the different groups according to fat mass and metabolic parameters. The hypothesis is that in humans the quantitative and /or qualitative disturbances of adipose tissue are associated with an increase of IL-7 levels and the development of insulin-resistance.

Awaited results and possible implications: this study will allow to better delineate the immune and inflammatory component associated with alterations of fat mass distribution and glucose metabolism. Our approach combining clinical investigation and ex vivo and laboratory analysis is original and should allow to better understand the cellular mechanisms responsible for the inflammatory process originated in white adipose tissue and accompanying the disorders of this tissue- more especially lipodystrophic syndromes - opening new therapeutic perspectives in common human diseases (obesity, diabetes) on the one hand, and a rare disease (lipodystrophy) on the other hand.

Keywords
Interleukin 7, adipose tissue
Medical subject headings
Lipodystrophy, Obesity, Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01784289
Study groupRoleWhat they receive
normalPatients with no overweight and no type 2 diabetes
lipodystrophypatients with a lipodystrophy, most are diabetics
obese non diabeticsPatients with obesity (BMI <30kg/m2), without diabetes
obese diabeticsPatients with obesity (BMI <30 kg/m2), with diabetes

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measure of blood Interleukin 7

    Measured: 1 day

Secondary outcomes (14)
  1. measure of blood Interleukins 2

    Measured: 1 day

  2. measure of blood interleukin 9

    Measured: 1 day

  3. measure of blood Interleukin 15

    Measured: 1 day

  4. measure of blood TNF

    Measured: 1 day

  5. measure of blood IL-1

    Measured: 1 day

  6. measure of blood IL-6

    Measured: 1 day

  7. measure of blood IL-8

    Measured: 1 day

  8. measure of blood IL-10

    Measured: 1 day

  9. measure of blood IL-18

    Measured: 1 day

  10. measure of blood leptin

    Measured: 1 day

  11. measure of blood adiponectin

    Measured: 1 day

  12. Blood count of monocytes/macrophages

    Measured: 1 day

  13. Blood count of dendritic cells

    Measured: 1 day

  14. Count of blood lymphocytes T

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Feb 2013 (estimated)
  2. Study startJun 2010
  3. Primary completionJun 2015
  4. Study completionJun 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
126 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01784289
Sponsor's protocol ID
2009_09/0941
Other IDs
2009-A01169-48, B91413-80, PHRC 2009/API
Acronym
IL-7norm
Status last verified
Feb 2017
First submitted
9 Aug 2011
Last updated
14 May 2026
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Lemaitre M, Chevalier B, Jannin A, Le Mapihan K, Boury S, Lion G, Labalette M, Vantyghem MC. Metabolic and immunological phenotype of rare lipomatoses: Dercum's disease and Roch-Leri mesosomatic lipomatosis. Orphanet J Rare Dis. 2021 Jun 29;16(1):290. doi: 10.1186/s13023-021-01920-3.

    PubMed 34187516

Questions about this trial

What is this clinical trial studying?

An observational study of Lipodystrophy and Obesity, run by University Hospital, Lille at 5 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measure of blood Interleukin 7 (time frame: 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01784289, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in